Drugs.com - Clinical Trials

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt...

Feb 10, 2025 - 21:28
 0
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt...
Read More

Tags:

Previous Article

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial of Bexoteg...

Next Article

Cosmetics brand Laura Mercier launches Apple Vision Pro shopping app

Related Posts

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics to Expand Phase 3 SELVA Clinical ...

Feb 13, 2025  0

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Novo Nordisk Successfully Completes Phase 1b/2a Trial w...

Feb 9, 2025  0

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma Announces Positive Results from ALLEVIATE-1...

Feb 9, 2025  0